The global market for Crohn`s Disease (CD) Therapy was estimated at US$12.7 Billion in 2023, and is projected to reach US$17.7 Billion by 2030, growing at a CAGR of 4.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Anti-TNF Biologics segment, which is expected to reach US$7.4 Billion by 2030 with a CAGR of a 5.8%. The Aminosalicyates segment is also set to grow at 2.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.5 Billion in 2023, and China, forecasted to grow at an impressive 4.5% CAGR to reach $2.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Crohn`s Disease (CD) Therapy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Crohn`s Disease (CD) Therapy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Crohn`s Disease (CD) Therapy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie, Inc., Amgen, Inc., AstraZeneca PLC, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 46 Featured):
- AbbVie, Inc.
- Amgen, Inc.
- AstraZeneca PLC
- Biogen, Inc.
- Boehringer Ingelheim International GmbH
- Celltrion Healthcare Co., Ltd.
- ChemoCentryx, Inc.
- Ferring Pharmaceuticals
- Johnson & Johnson
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
- Novo Nordisk A/S
- Pfizer, Inc.
- Takeda Pharmaceutical Co., Ltd.
- UCB SA
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned
- AbbVie, Inc.
- Amgen, Inc.
- AstraZeneca PLC
- Biogen, Inc.
- Boehringer Ingelheim International GmbH
- Celltrion Healthcare Co., Ltd.
- ChemoCentryx, Inc.
- Ferring Pharmaceuticals
- Johnson & Johnson
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
- Novo Nordisk A/S
- Pfizer, Inc.
- Takeda Pharmaceutical Co., Ltd.
- UCB SA
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 142 |
Published | November 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 12.7 Billion |
Forecasted Market Value ( USD | $ 17.7 Billion |
Compound Annual Growth Rate | 4.8% |
Regions Covered | Global |
No. of Companies Mentioned | 16 |